- Details
- Description
Packaging Size:
60C/bottle
Strength:
200mg&250mg
Composition:
Crizotinib
Treatment:
ALK+ non-small cell lung cancer (NSCLC) ,ROS1 + non-small cell lung cancer (NSCLC) ,ALK+ inflammatory myofibroblastic tumors (IMT) ,
Form:
Capsule
Brand:
Kayzoni
Quantity Unit:
200mg*60C/Bottle & 250mg*60C/Bottle
Manufacturer:
Tongmeng (Lao) Pharmaceutical & Food Co., Ltd.（TLPH）
Crizotinib is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1.
Non-Small Cell Lung Cancer
Indicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are anaplastic lymphoma kinase (ALK)- or ROS1-positive
250 mg PO BID
Continue until disease progression or unacceptable toxicity
Inflammatory Myofibroblastic tumors
Indicated for unresectable, recurrent, or refractory inflammatory myofibroblastic tumors (IMT) in adults who are ALK-positive
250 mg PO BID
Continue until disease progression or unacceptable toxicity
Dosage Modifications
- First dose reduction: 200 mg PO BID
- Second dose reduction: 250 mg PO qDay
- Unable to tolerate 250 mg PO qDay: Permanently discontinue
